Mode
Text Size
Log in / Sign up
N/A N=25 Randomized Treatment

Servo-Ventilation In-lab PSG Evaluation

Sleep Apnea Syndromes

Enrolled (actual)
25
Serious AEs
0.0%
Results posted
Mar 2019
Primary outcome: Primary: Average Apnea Hypopnea Index Among Different Polysomnography Devices. — 18.4; 25.4; 24.1; 19.2 events per hour

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Philips BiPAP AutoSV Advanced System One (Device); Modified Philips BiPAP ASV (Device); ResMed S7 VPAP Adapt (Device); ResMed S9 VPAP Adapt (Device)
Age
Adult, Older Adult · 21+ yrs
Sex
All
Sponsor
Philips Respironics
Primary completion
May 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Average Apnea Hypopnea Index Among Different Polysomnography Devices.
18.4; 25.4; 24.1; 19.2

Summary

Continuous Positive Airway Pressure (CPAP) is the most effective treatment for the Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS). CPAP stabilizes the airway and prevents instability and collapse. With a stable and patent airway, breathing continues in a normal manner, gas exchange is improved, and there is no disruption of sleep related to disturbed breathing. Auto Servo Ventilation (Auto SV) is a mode of positive airway pressure used to treat obstructive and complex central sleep apnea. The main features of the Auto SV mode include: * Normalization of ventilation by automatically adjusting Inspiratory Positive Airway Pressure (IPAP) pressure to achieve a target ventilation. IPAP is increased or decreased to help stabilize the ventilation. * Provision of timed, back-up breaths during central apneas. The optimal back-up rate is automatically determined by the device based on the patient's breathing. * Automatic control of Expiratory Positive Airway Pressure (EPAP) to treat obstructive events. Several manufacturers produce these types of devices. The algorithms used to determine the IPAP, EPAP and minimum respiratory rate are different. The largest number of these devices currently in use are the BiPAP AutoSV Advanced System One (Philips Respironics, Murrysville PA) and the Variable positive airway pressure (VPAP) Adapt (ResMed Corp., San Diego CA).

Eligibility Criteria

Inclusion Criteria

  • Ability to provide consent
  • Age ≥ 21
  • Currently prescribed servo ventilation therapy at home
  • At least two weeks of recent adherence and efficacy data from PAP device demonstrating adequate use of therapy (at least 4 hours of use per night and use on at least 9 of 14 nights)
  • Current device compliance report demonstrating residual Apnea-Hypopnea Index (AHI) of 5 or more

Exclusion Criteria

  • Participants who are acutely ill, medically complicated or who are medically unstable
  • Participants in whom PAP therapy is otherwise medically contraindicated
  • Participants who are claustrophobic
  • Symptomatic ("Symptomatic" defined as hospitalized for heart failure or a change in cardiac medications, within the last two months) chronic heart failure (NYHA 2-4) and reduced LVEF≤45%, AND moderate to severe predominant central sleep apnea
  • Participants with previously diagnosed respiratory failure or respiratory insufficiency and who are known to have elevated arterial carbon dioxide levels while awake (PaCO2 ≥ 55mmHg).
  • Participants requiring any kind of oxygen therapy
  • Participants who have had surgery of the upper airway, nose, sinus, eyes, or middle ear within the previous 90 days
  • Participants with untreated, non-OSA sleep disorders, including but not limited to; insomnia, periodic limb movement syndrome, or restless legs syndrome (PLMI > 10).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02808338). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search